These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Bhat SA; Czuczman MS Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657 [TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma]. Jourdan E; Richard B Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826 [TBL] [Abstract][Full Text] [Related]
6. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187 [TBL] [Abstract][Full Text] [Related]
7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642 [TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibody therapy for non-Hodgkin's lymphoma]. Paul F; Rossi JF; Cartron G Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313 [TBL] [Abstract][Full Text] [Related]
9. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. van Meerten T; Hagenbeek A Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518 [TBL] [Abstract][Full Text] [Related]
10. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Collins-Burow B; Santos ES Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647 [TBL] [Abstract][Full Text] [Related]
11. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
14. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108 [TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Jazirehi AR; Bonavida B Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036 [TBL] [Abstract][Full Text] [Related]
16. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Hainsworth JD Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459 [TBL] [Abstract][Full Text] [Related]
17. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469 [TBL] [Abstract][Full Text] [Related]
18. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Molina A Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705 [TBL] [Abstract][Full Text] [Related]
19. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Anderson DR; Grillo-López A; Varns C; Chambers KS; Hanna N Biochem Soc Trans; 1997 May; 25(2):705-8. PubMed ID: 9191187 [No Abstract] [Full Text] [Related]
20. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]